Mislabeled Bottles Trigger Recall of the ADHD Drug Zenzedi
By Physician’s Briefing Staff HealthDay Reporter
TUESDAY, Jan. 30, 2024 -- One lot of Zenzedi (dextroamphetamine sulfate) 30-mg tablets is being recalled after a pharmacist found antihistamine tablets (carbinoxamine) in a bottle labeled as Zenzedi, according to a recall notice issued by Azurity Pharmaceuticals Inc.
The recall comes amid an ongoing national shortage of attention-deficit/hyperactivity disorder (ADHD) drugs, creating further frustration for people with ADHD who have struggled to find medications for their condition.
The recall notice said that people who take carbinoxamine instead of Zenzedi have a higher risk for accidents or injuries and may have drowsiness, increased eye pressure, urinary obstruction, and thyroid disorder. The recalled lot has the lot number F230169A and an expiration date of June 2025.
Azurity added that it has not received any reports of serious injury related to the medication mix-up.
Consumers who have the recalled medication should return it to their pharmacy. Any adverse reactions to the drug should be reported to the U.S. Food and Drug Administration MedWatch Adverse Event Reporting program.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted January 2024
Read this next
ADHD Meds May Help Control Opioid Use Disorder in Pregnancy
TUESDAY, June 25, 2024 -- Psychostimulants may help opioid use disorder (OUD) outcomes in pregnant women, according to a study published online June 11 in Nature Mental...
FDA Approves First Liquid, Nonstimulant ADHD Treatment, Onyda XR
MONDAY, June 3, 2024 -- The U.S. Food and Drug Administration has approved once-daily Onyda XR (clonidine hydrochloride) as the first liquid, nonstimulant treatment for...
Pharmacological Treatment of ADHD May Cut Some Forms of Criminality
WEDNESDAY, May 29, 2024 -- Pharmacological treatment may reduce some types of criminality among adolescents and young adults with attention-deficit/hyperactivity disorder (ADHD)...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.